Analysts expect Translate Bio Inc (NASDAQ:TBIO) to post ($0.44) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Translate Bio’s earnings. The business is scheduled to report its next earnings results on Thursday, June 20th.
According to Zacks, analysts expect that Translate Bio will report full year earnings of ($1.52) per share for the current year, with EPS estimates ranging from ($1.74) to ($1.30). For the next financial year, analysts anticipate that the business will report earnings of ($1.74) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Translate Bio.
Translate Bio (NASDAQ:TBIO) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.09. The company had revenue of $1.18 million during the quarter, compared to the consensus estimate of $0.80 million.TBIO has been the topic of several recent research reports. HC Wainwright initiated coverage on Translate Bio in a research report on Monday, December 24th. They set a “buy” rating and a $21.00 price target on the stock. ValuEngine lowered Translate Bio from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Translate Bio has a consensus rating of “Buy” and a consensus target price of $22.75.
Shares of TBIO opened at $12.36 on Thursday. Translate Bio has a 12 month low of $4.81 and a 12 month high of $16.60. The company has a current ratio of 10.47, a quick ratio of 10.47 and a debt-to-equity ratio of 0.83. The firm has a market cap of $559.54 million and a price-to-earnings ratio of -3.40.
A number of hedge funds have recently bought and sold shares of the business. Baupost Group LLC MA increased its stake in Translate Bio by 237.5% in the 3rd quarter. Baupost Group LLC MA now owns 6,491,287 shares of the company’s stock worth $62,393,000 after buying an additional 4,568,211 shares during the period. Atlas Venture Advisors Inc. acquired a new position in Translate Bio in the fourth quarter valued at about $29,415,000. BlackRock Inc. lifted its position in Translate Bio by 130.2% in the fourth quarter. BlackRock Inc. now owns 982,405 shares of the company’s stock valued at $7,367,000 after buying an additional 555,635 shares during the last quarter. FMR LLC lifted its position in Translate Bio by 6.8% in the fourth quarter. FMR LLC now owns 6,771,313 shares of the company’s stock valued at $50,785,000 after buying an additional 433,952 shares during the last quarter. Finally, Vanguard Group Inc acquired a new position in Translate Bio in the third quarter valued at about $2,879,000. Hedge funds and other institutional investors own 59.27% of the company’s stock.
About Translate Bio
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Further Reading: Economic Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Translate Bio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Translate Bio and related companies with MarketBeat.com’s FREE daily email newsletter.